2592MO Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): Results from phase III part of a randomized, open-label, active-controlled phase II/III study (FRUSICA-2)
Year: 2025
Type: article
Source: Annals of Oncology
Institutions: Fudan University Shanghai Cancer Center, Peking University First Hospital, Capital Medical University, Beijing Chao-Yang Hospital, Capital Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Hunan Cancer Hospital, Fudan University, Zhongshan Hospital, Henan Cancer Hospital, Liaoning Cancer Hospital & Institute, Shandong Tumor Hospital, First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Peking University Third Hospital, West China Hospital of Sichuan University, Third Affiliated Hospital of Harbin Medical University, Jiangsu Cancer Hospital, First Hospital of China Medical University, HUTCHMED (China) Limited (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415940574